Search Results

Ikena Oncology, Inc. and Pionyr Immunotherapeutics, Inc. announced the closing of Ikena’s acquisition of Pionyr in an all-stock transaction.

Pionyr Immunotherapeutics, Inc., a company developing first-in-class Myeloid TuningTM antibody therapeutics that enhance the body’s anti-tumor immunity by altering, or “tuning,” immune cells within the tumor microenvironment, announced that Pionyr and Gilead Sciences, Inc. have mutually agreed to change their 2020 exclusive option agreements.

Pionyr Immunotherapeutics, Inc. announced that PY159, a monoclonal antibody targeting TREM1, was well-tolerated with signals of durable therapeutic activity in a Phase 1a dose-escalation study as a single agent and in combination with pembrolizumab.

Pionyr Immunotherapeutics, Inc. will present pre-clinical data showing the potential for its PY265 program to treat solid tumors, as a single agent and in combination with checkpoint inhibitor (CPI) therapy.

Pionyr Immunotherapeutics, Inc. announced today that Johanna Joyce, Ph.D., Olivier Elemento, Ph.D., and Michael Quigley, Ph.D., will join Miriam Merad, Ph.D., as members of Pionyr’s Scientific Advisory Board.

OSE Immunotherapeutics Provides Business and Corporate Update Three pharmaceutical agreements signed during the last three months.

Pionyr Immunotherapeutics, Inc announced it has begun dosing patients in its Phase 1b expansion study investigating PY159 in patients with prioritized cancer types: ovarian cancer, pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC), HR+HER2- breast cancer, head and neck squamous cell carcinomas (HNSCC), and colorectal cancer (CRC).

OSE Immunotherapeutics Announces Publication of Preclinical Efficacy Results with Lusvertikimab in Acute Lymphoblastic Leukemia in the Journal ‘Blood’

OSE Immunotherapeutics SA, announced that the Company has entered into a commercial and revenue sharing agreement with leading global cancer center.